The Impact of Expanded Weight-Loss Drug Coverage in the U.S

As healthcare policies evolve, they often spark significant changes in medical markets, public health, and societal expectations. President Joe Biden's recent proposal to broaden Medicare and Medicaid coverage for weight-loss medications is poised to reshape the American healthcare landscape. Here's a look at the potential ripple effects this ambitious plan could create for patients, industries, and the economy.

Biden’s administration seeks to make weight-loss drugs, particularly GLP-1 medications like Ozempic and Wegovy, more accessible to millions of Americans. If implemented in 2026, the plan would cover approximately 7.5 million additional people, including seniors and lower-income households. The initiative could slash out-of-pocket costs by up to 95%, significantly lowering the financial barrier for treatment.

Yet, the future of this proposal lies with the incoming administration. With competing views on government spending and healthcare priorities, the outcome remains uncertain.

Percent of adults aged 20 and older with obesity, 2000-23  Source: ING report, US National Health and Nutrition Examination SurveyWhy Weight-Loss Drugs MatterObesity, a long-standing public health challenge, not only burdens individuals but also strains societal resources. The introduction of GLP-1 drugs has already contributed to a slight decline in U.S. obesity rates, particularly among the college-educated demographic with greater access to these treatments. By expanding coverage, the initiative aims to amplify these positive trends.

However, the broader societal cost of obesity encompasses lost productivity and diminished quality of life, factors that drugs alone cannot address. Integrating preventive measures alongside medication will be key to sustainable success.

 Source: ING Report, Peterson-KFF; Hecker et al. (2022); Cawley et al. (2021); Effertz et al. (2016); Konnopka et al. (2010); World Bank; Novo Nordisk; ING CalculationsWinners and Losers in the Healthcare EcosystemExpanding access to weight-loss drugs is expected to drive higher demand, benefiting pharmaceutical giants like Eli Lilly and Novo Nordisk. Yet not all sectors will thrive under this shift. For example:

Winners: Orthopedical manufacturers may see increased demand for joint replacements as weight loss improves eligibility for surgery.Losers: Medical device makers and healthcare providers specializing in obesity-related procedures, such as bariatric surgeries, may face reduced demand.The healthcare sector must brace for these changes, adjusting strategies to meet evolving patient needs and market dynamics.

The Supply ChallengeWith demand for GLP-1 drugs set to soar, questions about supply chain readiness come to the forefront. While major manufacturers are investing billions in production facilities, the risk of shortages looms, especially as diabetics continue to rely on these medications. Ensuring equitable distribution will require ongoing coordination among stakeholders.

The Long-Term VisionWhile the upfront cost of expanded coverage is significant—an estimated $35 billion by 2034—the potential long-term benefits are compelling. Healthier populations could lead to reduced healthcare spending and greater economic productivity. Policymakers and healthcare leaders must weigh these trade-offs to guide decisions that align with both fiscal responsibility and public health goals.

The journey toward broader access to weight-loss medications reflects a broader struggle to balance innovation, accessibility, and equity in healthcare. As policymakers and industries navigate this pivotal moment, the choices they make will influence not just the healthcare landscape, but the well-being of millions.

Sources: ING Think, the winners and losers of Biden’s plans to expand coverage of weight-loss drugs. Published November 28, 2024. Accessed for analysis and interpretation.

This content may have been written by a third party. ACY makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplies by any third-party. This content is information only, and does not constitute financial, investment or other advice on which you can rely.